Literature DB >> 180050

Suppression by cyproheptadine of human growth hormone and cortisol secretion during sleep.

K Chihara, Y Kato, K Maeda, S Matsukura, H Imura.   

Abstract

The effect of cyproheptadine on plasma growth hormone and cortisol levels was studied in seven male volunteers with polygraphic sleep monitoring. Sleep-related growth hormone release was completely inhibited in three of the seven normal subjects by the intravenous infusion of cyproheptadine (5 mg) which was started at the onset of sleep. In the other four, growth hormone release during sleep was significantly decreased or delayed by cyproheptadine when the drug infusion was started at 7:00 p.m., 1-2 h before the onset of sleep. The usual increase in plasma cortisol in the early morning was completely suppressed in all five subjects given cyproheptadine infusions from 4:00 to 7:00 a.m. The intravenous infusion of cyproheptadine increased slow wave sleep, although the time from sleep onset to the first occurrence of slow wave sleep was not affected. In contrast, rapid eye movement sleep was significantly decreased by cyproheptadine. These results suggest that cyproheptadine inhibits growth hormone and ACTH secretion during sleep in man, possibly by antagonizing serotoninergic mechanisms although other actions of the drug are not ruled out.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 180050      PMCID: PMC436797          DOI: 10.1172/JCI108408

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  Effect of cyproheptadine on human growth hormone secretion.

Authors:  Y Nakai; H Imura; H Sakurai; H Kurahachi; T Yoshimi
Journal:  J Clin Endocrinol Metab       Date:  1974-03       Impact factor: 5.958

2.  Growth hormone regulation by melatonin and serotonin.

Authors:  G A Smythe; L Lazarus
Journal:  Nature       Date:  1973-07-27       Impact factor: 49.962

3.  Experimental modification of the sleep-induced peak of growth hormone secretion.

Authors:  C Lucke; S M Glick
Journal:  J Clin Endocrinol Metab       Date:  1971-06       Impact factor: 5.958

4.  The role of monoamines and acetylcholine-containing neurons in the regulation of the sleep-waking cycle.

Authors:  M Jouvet
Journal:  Ergeb Physiol       Date:  1972

5.  Adrenergic and serotoninergic control of growth hormone secretion in adult male rats.

Authors:  R Collu; F Fraschini; P Visconti; L Martini
Journal:  Endocrinology       Date:  1972-05       Impact factor: 4.736

6.  Inhibition of hypoglycemia-induced growth hormone secretion by the serotonin antagonists cyproheptadine and methysergide.

Authors:  C H Bivens; H E Lebovitz; J M Feldman
Journal:  N Engl J Med       Date:  1973-08-02       Impact factor: 91.245

7.  Inhibition of the sleep-related peak in physiologic human growth hormone release by somatostatin.

Authors:  D C Parker; L G Rossman; T M Siler; J Rivier; S S Yen; R Guillemin
Journal:  J Clin Endocrinol Metab       Date:  1974-03       Impact factor: 5.958

8.  Effect of 5-hydroxytryptophan (5-HTP) on growth hormone and ACTH release in man.

Authors:  H Imura; Y Nakai; T Yoshimi
Journal:  J Clin Endocrinol Metab       Date:  1973-01       Impact factor: 5.958

9.  Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone.

Authors:  P Brazeau; W Vale; R Burgus; N Ling; M Butcher; J Rivier; R Guillemin
Journal:  Science       Date:  1973-01-05       Impact factor: 47.728

10.  Suppression of human growth hormone secretion by melatonin and cyproheptadine.

Authors:  G A Smythe; L Lazarus
Journal:  J Clin Invest       Date:  1974-07       Impact factor: 14.808

View more
  8 in total

1.  The effect of TRH on the release of TSH, PRL and GH in man under basal conditions and following methysergide.

Authors:  R Collu
Journal:  J Endocrinol Invest       Date:  1978-04       Impact factor: 4.256

Review 2.  Neuroendocrine markers of CNS drug effects.

Authors:  E C Johnstone; I N Ferrier
Journal:  Br J Clin Pharmacol       Date:  1980-07       Impact factor: 4.335

3.  Hypothalamic control of GH secretion: pathophysiology and clinical implications.

Authors:  H J Quabbe
Journal:  Acta Neurochir (Wien)       Date:  1985       Impact factor: 2.216

4.  Production of corticotrophin releasing hormone by the isolated hypothalamus of the rat.

Authors:  J C Buckingham; J R Hodges
Journal:  J Physiol       Date:  1977-11       Impact factor: 5.182

5.  Improved oral glucose tolerance following antiserotonin treatment in patients with chemical diabetes.

Authors:  C Ferrari; C Barbieri; R Caldara; V Magnoni; G P Testori; M Romussi
Journal:  Eur J Clin Pharmacol       Date:  1979-07       Impact factor: 2.953

6.  Methoscopolamine inhibition of sleep-related growth hormone secretion. Evidence for a cholinergic secretory mechanism.

Authors:  W B Mendelson; N Sitaram; R J Wyatt; J C Gillin; L S Jacobs
Journal:  J Clin Invest       Date:  1978-06       Impact factor: 14.808

7.  Effects of psychotropic drugs (desimipramine, chlorimipramine, sulpiride and diazepam) on the human HPA axis.

Authors:  G Laakmann; M Wittmann; M Gugath; O A Mueller; J Treusch; U Wahlster; G K Stalla
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

8.  Antiserotonergic inhibition of calcitonin-induced increase of beta-endorphin, ACTH, and cortisol secretion.

Authors:  L Laurian; Z Oberman; E Hoerer; E Graf
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.